CWC Advisors’s TG Therapeutics TGTX Stock Holding History

CWC Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Hold	19,081	–	–	0.47%	57
2026 Q1	$634K	Buy	19,081 +5,848	+44%	+$174K	0.3%	80
2025 Q4	$394K	Sell	13,233 -992	-7%	-$32.4K	0.19%	110
2025 Q3	$514K	Buy	14,225 +525	+4%	+$17.3K	0.25%	93
2025 Q2	$493K	Hold	13,700	–	–	0.25%	82
2025 Q1	$540K	Hold	13,700	–	–	0.31%	74
2024 Q4	$412K	Sell	13,700 -2,450	-15%	-$70.3K	0.41%	69
2024 Q3	$378K	Buy	+16,150	New	+$353K	0.37%	75

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

CWC Advisors's TGTX Position: Q2 2026 in Review

CWC Advisors held its TG Therapeutics (TGTX) position steady in Q2 2026 at 19,081 shares worth $1.05M. The position accounts for 0.47% of the portfolio, ranked #57.

CWC Advisors first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

CWC Advisors held 19,081 shares of TG Therapeutics worth $1.05M as of Q2 2026.
CWC Advisors left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.47% of CWC Advisors's portfolio in Q2 2026, its #57 holding.
CWC Advisors first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on CWC Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.